Pylori Infection In Stomach Research Articles

An observational study to assess the Helicobacter pylori infection rates in patients with cholelithiasis

Background: Cholelithiasis and chronic cholecystitis cholelithiasis is fairly common all around the world. Since chronic inflammation causes repeated trauma to the gallbladder mucosa and DNA damage led by high or abnormal bile acid exposure, gallstones are closely related to the development of hepatobiliary cancers. After cholecystectomy, some patients experience ongoing upper abdomen pain, which is distressing for the surgeons and raises the possibility of a concomitant upper gastrointestinal issue, which in most cases turned out to be peptic ulcer disease. Numerous studies have found various Helicobacter species in the gallbladder tissue, gallstones, and bile taken from the gallbladder. We conducted this study to assess the relationship between cholelithiasis and H. pylori infection in the stomach. Ascending infection of H. pylori from the stomach and duodenum to biliary tree may have function in development of gall stone production and hepatobiliary carcinomas. Methods: Hospital based cross sectional observational study on patients admitted in surgical wards of SMS Hospital Jaipur for laparoscopic cholecystectomy. All patients underwent UGI and gastric antral biopsy followed by laparoscopic cholecystectomy, gastric mucosa and GB mucosa were subjected to Warthin starry silver stain for detection of H. pylori. Results: Out of 116 patients who underwent upper GI endoscopy followed by laparoscopic cholecystectomy, 29 (25%) patients were positive for H. pylori infection. Conclusions: This study shows significant positive co-relation between H. pylori infection in stomach, gall bladder to chronic cholecystitis and cholelithiasis, which signifies gastric colonisation of H. pylori has it’s role in biliary pathologies through ascending infection, the effectiveness of H. pylori eradication therapy in preventing these pathologies need to be studied further.

Association of Chronic Periodontitis with Helicobacter pylori Infection in Stomach or Mouth: A Systematic Review and Meta-Analysis.

Helicobacter pylori (H. pylori) infection and periodontitis are both inflammatory conditions associated with systemic diseases. Researchers have attempted to investigate the correlation between them. This systematic review and meta-analyses were conducted to investigate the association of H. pylori infection in the stomach and/or in subgingival plaque and gingival crevicular fluid with chronic periodontitis. The protocol was created according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) statement. The study was designed according to the Cochrane criteria. A comprehensive literature search was performed in MEDLINE, Scopus, and CENTRAL, combined with hand-searching and assessment of gray literature. The meta-analysis of the included studies was made by the Review Manager (RevMan) 5.4 software. The effect measure of the outcome was odds ratios with 95% confidence intervals. Heterogeneity was assessed by chi-square and I2. Four observational studies involving 818 subjects were included in this meta-analysis. The odds of oral H. pylori presence were higher in patients with chronic periodontitis, compared to healthy controls, with an odds ratio of 1.87 (95% confidence interval 0.85-4.10; p = 0.12). The odds of the presence of H. pylori in the stomach also were higher in patients with chronic periodontitis, with an odds ratio of 1.80 (95% confidence interval 0.82-3.95; p = 0.15). There is no evidence for an association between chronic periodontitis and the prevalence of H. pylori, detected either in subgingival plaque and gingival crevicular fluid or in the stomach.

Gastrointestinal microbiome in the context of Helicobacter pylori infection in stomach and gastroduodenal diseases.

Infectious origins of a set of severe gastroduodenal diseases viz. gastritis, duodenal ulcer, gastric ulcer, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma were appreciated only after the discovery of H. pylori in 1983. In the past two decades, however, findings from many laboratories suggest that apart from H. pylori, several of the trillions of microbes that populate the human gastrointestinal tract and form microbiomes of the respective niches (like oral microbiome, esophageal microbiome, gastric microbiome and intestinal microbiome) may also participate in maintaining the healthy state of stomach and duodenum. Dysbiosis leading to alteration in the relative abundance of the key gastrointestinal microbes is associated with severe gastric diseases. For instance, an increased abundance of genera like Leptotrichia, Prevotella and Veillonella in gastric microbiome and a decreased abundance of Bifidobacterium in intestinal microbiome are associated with gastric cancer. H. pylori infection, apart from causing direct harm to the gastric epithelium by its virulence proteins like vacuolating cytotoxin A (VacA) and cytotoxin associated gene A (CagA), is also capable of triggering dysbiosis in stomach and intestinal microbiomes. In this chapter, we have discussed the possible roles of bacteria, viruses, fungi, archaea, protozoa and helminths in human gastrointestinal tracts in the context of H. pylori infection in stomach and various gastroduodenal diseases.

Low Bifidobacterium Abundance in the Lower Gut Microbiota Is Associated With Helicobacter pylori-Related Gastric Ulcer and Gastric Cancer.

Helicobacter pylori infection in stomach leads to gastric cancer, gastric ulcer, and duodenal ulcer. More than 1 million people die each year due to these diseases, but why most H. pylori-infected individuals remain asymptomatic while a certain proportion develops such severe gastric diseases remained an enigma. Several studies indicated that gastric and intestinal microbiota may play a critical role in the development of the H. pylori-associated diseases. However, no specific microbe in the gastric or intestinal microbiota has been clearly linked to H. pylori infection and related gastric diseases. Here, we studied H. pylori infection, its virulence genes, the intestinal microbiota, and the clinical status of Trivandrum residents (N = 375) in southwestern India by standard H. pylori culture, PCR genotype, Sanger sequencing, and microbiome analyses using Illumina Miseq and Nanopore GridION. Our analyses revealed that gastric colonization by virulent H. pylori strains (vacAs1i1m1cagA+) is necessary but not sufficient for developing these diseases. Conversely, distinct microbial pools exist in the lower gut of the H. pylori-infected vs. H. pylori-non-infected individuals. Bifidobacterium (belonging to the phylum Actinobacteria) and Bacteroides (belonging to the phylum Bacteroidetes) were present in lower relative abundance for the H. pylori+ group than the H. pylori- group (p < 0.05). On the contrary, for the H. pylori+ group, genus Dialister (bacteria belonging to the phylum Firmicutes) and genus Prevotella (bacteria belonging to the phylum Bacteroidetes) were present in higher abundance compared to the H. pylori- group (p < 0.05). Notably, those who carried H. pylori in the stomach and had developed aggressive gastric diseases also had extremely low relative abundance (p < 0.05) of several Bifidobacterium species (e.g., B. adolescentis, B. longum) in the lower gut suggesting a protective role of Bifidobacterium. Our results show the link between lower gastrointestinal microbes and upper gastrointestinal diseases. Moreover, the results are important for developing effective probiotic and early prognosis of severe gastric diseases.

Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative

The amoxicillin-UCCs-2/TPP nanoparticles constructed with ureido-modified chitosan derivative UCCs-2 and sodium tripolyphosphate (TPP) played an important role to deliver drug to achieve more efficacious and specific eradication of Helicobacterpylori (H. pylori) in vitro. In this study, the anti-H. pylori effectiveness in vivo and uptake mechanism was investigated in details, including the effect of temperature, pH values and the addition of competitive substrate urea on uptake. Compared with unmodified nanoparticles, a more efficacious and specific anti-H. pylori activities were obtained in vivo by using this biological chitosan derivative UCCs-2. Histological staining and immunological analysis verified that the amoxicillin-UCCs-2/TPP nanoparticles could diminish the proinflammatory cytokines levels and alleviate the inflammatory damages caused by H. pylori infection. The uredio-modified nanoparticles also have favorable gastric retention property, which is beneficial for the oral drug delivery to targeted eradicate H. pylori infection in stomach. These findings suggest that this targeted drug delivery system may serve for specific treatment of H. pylori infection both in vitro and in vivo, which can also be used as promising nanocarriers for other therapeutic reagents to target H. pylori.

Fermented Foods: Are They Tasty Medicines for Helicobacter pylori Associated Peptic Ulcer and Gastric Cancer?

More than a million people die every year due to gastric cancer and peptic ulcer. Helicobacter pylori infection in stomach is the most important reason for these diseases. Interestingly, only 10–20% of the H. pylori infected individuals suffer from these gastric diseases and rest of the infected individuals remain asymptomatic. The genotypes of H. pylori, host genetic background, lifestyle including smoking and diet may determine clinical outcomes. People from different geographical regions have different food habits, which also include several unique fermented products of plant and animal origins. When consumed raw, the fermented foods bring in fresh inocula of microbes to gastrointestinal tract and several strains of these microbes, like Lactobacillus and Saccharomyces are known probiotics. In vitro and in vivo experiments as well as clinical trials suggest that several probiotics have anti-H. pylori effects. Here we discuss the possibility of using natural probiotics present in traditional fermented food and beverages to obtain protection against H. pylori induced gastric diseases.

口腔幽门螺杆菌尿素酶的检测及其临床意义

幽门螺杆菌(Hp)感染诊断方法很多，各种诊断方法有其各自的特点，但传统Hp感染的诊断方法，主要适用于胃Hp感染的检测，对口腔Hp感染难以做出稳定的检测结果，甚至存在检测盲区。唾液幽门螺杆菌抗原测试板(HPS)，是应用胶体金层析式双抗体夹心法技术，采用Hp尿素酶单克隆抗体，定性检测人体唾液中相应Hp产生的尿素酶，主要应用于口腔Hp感染的检测，具有较高的敏感性和特异性，操作简便、快捷，可在实验室外进行检测等特点。HPS与UBT联合检测，可大致区分口腔Hp感染合并胃Hp感染、单纯口腔Hp感染、单纯胃Hp感染，为临床制定更完善的、全新的Hp根除方案提供实验诊断依据。 There are number of diagnostic methods detecting Helicobacter pylori (H. pylori) infection. Each has their own character, however standard diagnosis technology apply in detecting H. pylori infection of stomach, not suitable for diagnosis of oral infection. For example, C13, C14 UBT test had been utilized as a gold standard for diagnosis of H. pylori infection in stomach more than two decades, however they have blinded zone detecting oral H. pylori infection. A simple noninvasive, new technology, H. pylori saliva antigen test (HPS) to detecting oral infection with a clean view of the line linking oral and stomach H. pylori infection. HPS is a sandwich immunoassay test, which utilizes an unique antibodies to selectively identify H. pylori Urease in saliva. The HPS technology has high sensitivity and specificity. It is very simple procedure of test and the results can be obtained within few minutes. It is suitable for lab use and over the counter. The combination uses of HPS and UBT can classify both oral and stomach infection, or simple oral infection or simple stomach infection. By this technology we can make an revolutionary treatment plan for cure H. pylori infection.

Relationship of gastric Helicobacter pylori infection to Barrett's esophagus and gastro-esophageal reflux disease in Chinese.

To evaluate the relationship of Helicobacter pylori infection to reflux esophagitis (RE), Barrett's esophagus (BE) and gastric intestinal metaplasia (IM). RE, BE and gastric IM were determined by upper endoscopy. Patients were divided into 2 groups; those with squamocolumnar junction (SCJ) beyond gastroesophageal junction (GEJ) > =3 cm (group A), and those with SCJ beyond GEJ <3 cm (group B). Biopsy specimens were obtained endoscopically from just below the SCJ, gastric antrum along the greater and lesser curvature. Pathological changes and H pylori infection were determined by HE staining, Alcian blue staining and Giemsa staining. The prevalence of H pylori infection was 46.93%. There was no difference in the prevalence between males and females. The prevalence of H pylori infection decreased stepwise significantly from RE grade I to III. There was no difference in the prevalence between the two groups, and between long-segment and short-segment BE. In distal stomach, prevalence of H pylori infection was significantly higher in patients with IM than those without IM. There is a protective role of H pylori infection to GERD. There may be no relationship between H pylori infection of stomach and BE. H pylori infection is associated with the development of IM in the distal stomach.

Effect of Concomitant18O in13C-Urea on the Urea breath test

Helicobacter pylori infection in stomach has been extensively assessed by the 13C-urea breath test (UBT) with infra-red or mass spectrometer. However, analyses of commercially available 13C-urea for UBT showed about 10 atom% of 18O abundance. It is therefore very important to investigate the 18O-isotope effect on UBT. Using a mass spectrometer, breath samples of UBT were analyzed to investigate the change of mass spectra by the isotopic exchange reaction between 18O of carbon dioxide and 16O of water. As the result, the 18O content of 13C, 18O-carbon dioxide exhaled in UBT reached its natural abundance level immediately after the administration of 13C, 18O-urea. It was concluded that the 18O content of 13C, 18O-urea has no effect on UBT using either infra-red or mass spectroscopy. Copyright © 2000 John Wiley & Sons, Ltd.